Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study

Michelle M Mielke, Walter Maetzler, Norman J. Haughey, Veera V R Bandaru, Rodolfo Savica, Christian Deuschle, Thomas Gasser, Ann Kathrin Hauser, Susanne Gräber-Sultan, Erwin Schleicher, Daniela Berg, Inga Liepelt-Scarfone

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background:Mutations in the gene coding for glucocerebrosidase (GBA), which metabolizes glucosylceramide (a monohexosylceramide) into glucose and ceramide, is the most common genetic risk factor for sporadic Parkinson's disease (PD). GBA mutation carriers are more likely to have an earlier age of onset and to develop cognitive impairment and dementia. We hypothesized that plasma levels of lipids involved in ceramide metabolism would also be altered in PD non-GBA mutation carriers and associated with worse cognition.Methods:Plasma ceramide, monohexosylceramide, and lactosylceramide levels in 26 cognitively normal PD patients, 26 PD patients with cognitive impairment or dementia, and 5 cognitively normal non-PD controls were determined by LC/ESI/MS/MS.Results:Levels of all lipid species were higher in PD patients versus controls. Among PD patients, levels of ceramide C16:0, C18:0, C20:0, C22:0, and C24:1 and monohexosylceramide C16:0, C20:0 and C24:0 species were higher (all P<0.05) in those with versus without cognitive impairment.Conclusion:These results suggest that plasma ceramide and monohexosylceramide metabolism is altered in PD non-GBA mutation carriers and that higher levels are associated with worse cognition. Additional studies with larger sample sizes, including cognitively normal controls, are needed to confirm these findings.

Original languageEnglish (US)
Article numbere73094
JournalPLoS One
Volume8
Issue number9
DOIs
StatePublished - Sep 18 2013

Fingerprint

Glucosylceramides
ceramides
Ceramides
Parkinson disease
Metabolism
Parkinson Disease
Plasmas
metabolism
Glucosylceramidase
mutation
Mutation
dementia
cognition
Cognition
Dementia
Disease control
Lipids
lipids
Cognitive Dysfunction
Age of Onset

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment : A Pilot Study. / Mielke, Michelle M; Maetzler, Walter; Haughey, Norman J.; Bandaru, Veera V R; Savica, Rodolfo; Deuschle, Christian; Gasser, Thomas; Hauser, Ann Kathrin; Gräber-Sultan, Susanne; Schleicher, Erwin; Berg, Daniela; Liepelt-Scarfone, Inga.

In: PLoS One, Vol. 8, No. 9, e73094, 18.09.2013.

Research output: Contribution to journalArticle

Mielke, MM, Maetzler, W, Haughey, NJ, Bandaru, VVR, Savica, R, Deuschle, C, Gasser, T, Hauser, AK, Gräber-Sultan, S, Schleicher, E, Berg, D & Liepelt-Scarfone, I 2013, 'Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study', PLoS One, vol. 8, no. 9, e73094. https://doi.org/10.1371/journal.pone.0073094
Mielke, Michelle M ; Maetzler, Walter ; Haughey, Norman J. ; Bandaru, Veera V R ; Savica, Rodolfo ; Deuschle, Christian ; Gasser, Thomas ; Hauser, Ann Kathrin ; Gräber-Sultan, Susanne ; Schleicher, Erwin ; Berg, Daniela ; Liepelt-Scarfone, Inga. / Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment : A Pilot Study. In: PLoS One. 2013 ; Vol. 8, No. 9.
@article{1331e290750d47a6b6cd64acb198aed2,
title = "Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study",
abstract = "Background:Mutations in the gene coding for glucocerebrosidase (GBA), which metabolizes glucosylceramide (a monohexosylceramide) into glucose and ceramide, is the most common genetic risk factor for sporadic Parkinson's disease (PD). GBA mutation carriers are more likely to have an earlier age of onset and to develop cognitive impairment and dementia. We hypothesized that plasma levels of lipids involved in ceramide metabolism would also be altered in PD non-GBA mutation carriers and associated with worse cognition.Methods:Plasma ceramide, monohexosylceramide, and lactosylceramide levels in 26 cognitively normal PD patients, 26 PD patients with cognitive impairment or dementia, and 5 cognitively normal non-PD controls were determined by LC/ESI/MS/MS.Results:Levels of all lipid species were higher in PD patients versus controls. Among PD patients, levels of ceramide C16:0, C18:0, C20:0, C22:0, and C24:1 and monohexosylceramide C16:0, C20:0 and C24:0 species were higher (all P<0.05) in those with versus without cognitive impairment.Conclusion:These results suggest that plasma ceramide and monohexosylceramide metabolism is altered in PD non-GBA mutation carriers and that higher levels are associated with worse cognition. Additional studies with larger sample sizes, including cognitively normal controls, are needed to confirm these findings.",
author = "Mielke, {Michelle M} and Walter Maetzler and Haughey, {Norman J.} and Bandaru, {Veera V R} and Rodolfo Savica and Christian Deuschle and Thomas Gasser and Hauser, {Ann Kathrin} and Susanne Gr{\"a}ber-Sultan and Erwin Schleicher and Daniela Berg and Inga Liepelt-Scarfone",
year = "2013",
month = "9",
day = "18",
doi = "10.1371/journal.pone.0073094",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment

T2 - A Pilot Study

AU - Mielke, Michelle M

AU - Maetzler, Walter

AU - Haughey, Norman J.

AU - Bandaru, Veera V R

AU - Savica, Rodolfo

AU - Deuschle, Christian

AU - Gasser, Thomas

AU - Hauser, Ann Kathrin

AU - Gräber-Sultan, Susanne

AU - Schleicher, Erwin

AU - Berg, Daniela

AU - Liepelt-Scarfone, Inga

PY - 2013/9/18

Y1 - 2013/9/18

N2 - Background:Mutations in the gene coding for glucocerebrosidase (GBA), which metabolizes glucosylceramide (a monohexosylceramide) into glucose and ceramide, is the most common genetic risk factor for sporadic Parkinson's disease (PD). GBA mutation carriers are more likely to have an earlier age of onset and to develop cognitive impairment and dementia. We hypothesized that plasma levels of lipids involved in ceramide metabolism would also be altered in PD non-GBA mutation carriers and associated with worse cognition.Methods:Plasma ceramide, monohexosylceramide, and lactosylceramide levels in 26 cognitively normal PD patients, 26 PD patients with cognitive impairment or dementia, and 5 cognitively normal non-PD controls were determined by LC/ESI/MS/MS.Results:Levels of all lipid species were higher in PD patients versus controls. Among PD patients, levels of ceramide C16:0, C18:0, C20:0, C22:0, and C24:1 and monohexosylceramide C16:0, C20:0 and C24:0 species were higher (all P<0.05) in those with versus without cognitive impairment.Conclusion:These results suggest that plasma ceramide and monohexosylceramide metabolism is altered in PD non-GBA mutation carriers and that higher levels are associated with worse cognition. Additional studies with larger sample sizes, including cognitively normal controls, are needed to confirm these findings.

AB - Background:Mutations in the gene coding for glucocerebrosidase (GBA), which metabolizes glucosylceramide (a monohexosylceramide) into glucose and ceramide, is the most common genetic risk factor for sporadic Parkinson's disease (PD). GBA mutation carriers are more likely to have an earlier age of onset and to develop cognitive impairment and dementia. We hypothesized that plasma levels of lipids involved in ceramide metabolism would also be altered in PD non-GBA mutation carriers and associated with worse cognition.Methods:Plasma ceramide, monohexosylceramide, and lactosylceramide levels in 26 cognitively normal PD patients, 26 PD patients with cognitive impairment or dementia, and 5 cognitively normal non-PD controls were determined by LC/ESI/MS/MS.Results:Levels of all lipid species were higher in PD patients versus controls. Among PD patients, levels of ceramide C16:0, C18:0, C20:0, C22:0, and C24:1 and monohexosylceramide C16:0, C20:0 and C24:0 species were higher (all P<0.05) in those with versus without cognitive impairment.Conclusion:These results suggest that plasma ceramide and monohexosylceramide metabolism is altered in PD non-GBA mutation carriers and that higher levels are associated with worse cognition. Additional studies with larger sample sizes, including cognitively normal controls, are needed to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=84884264199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884264199&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0073094

DO - 10.1371/journal.pone.0073094

M3 - Article

C2 - 24058461

AN - SCOPUS:84884264199

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e73094

ER -